90 related articles for article (PubMed ID: 8578252)
1. How do we follow patients with Ta grade 1-111 bladder tumors in Denmark?
Nielsen KT; Lund L; Mommsen S; Olesen S
Scand J Urol Nephrol Suppl; 1995; 172():27-31. PubMed ID: 8578252
[TBL] [Abstract][Full Text] [Related]
2. Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial.
Olsen LH; Genster HG
Scand J Urol Nephrol Suppl; 1995; 172():33-6. PubMed ID: 8578253
[TBL] [Abstract][Full Text] [Related]
3. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
4. Watchful waiting policy in recurrent Ta G1 bladder tumors.
Gofrit ON; Pode D; Lazar A; Katz R; Shapiro A
Eur Urol; 2006 Feb; 49(2):303-6; discussion 306-7. PubMed ID: 16413659
[TBL] [Abstract][Full Text] [Related]
5. Management of neurogenic bladder patients in The Netherlands: do urologists follow guidelines?
Rikken B; Blok BF
Neurourol Urodyn; 2008; 27(8):758-62. PubMed ID: 18508332
[TBL] [Abstract][Full Text] [Related]
6. Clinical practice and evidence in endoscopic treatment of bleeding peptic gastroduodenal ulcer.
Adamsen S; Bendix J; Kallehave F; Moesgaard F; Nilsson T; Wille-Jørgensen P
Scand J Gastroenterol; 2007 Mar; 42(3):318-23. PubMed ID: 17354110
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer.
Canales BK; Anderson JK; Premoli J; Slaton JW
J Urol; 2006 Jan; 175(1):74-7. PubMed ID: 16406874
[TBL] [Abstract][Full Text] [Related]
8. [Disease classification--how are bladder tumors registered? A questionnaire].
Eldrup J; Borly L; Rasmussen HM; Amstrup JH
Ugeskr Laeger; 1995 Aug; 157(35):4816-8. PubMed ID: 7676518
[TBL] [Abstract][Full Text] [Related]
9. Conservative management of low risk superficial bladder tumors.
Pruthi RS; Baldwin N; Bhalani V; Wallen EM
J Urol; 2008 Jan; 179(1):87-90; discussion 90. PubMed ID: 17997444
[TBL] [Abstract][Full Text] [Related]
10. [Prophylactic contralateral orchiopexy in patients with testicular torsion].
Nielsen TG; Holm M; Meyhoff HH
Ugeskr Laeger; 1999 Aug; 161(35):4880-2. PubMed ID: 10778317
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice.
Vrooman OP; Witjes JA
Curr Opin Urol; 2010 Sep; 20(5):437-42. PubMed ID: 20657286
[TBL] [Abstract][Full Text] [Related]
12. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
13. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
14. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
15. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
16. [Children with commotio cerebri at paediatric departments in Denmark].
Rønde G; Blichfeldt S
Ugeskr Laeger; 2008 May; 170(20):1740-3. PubMed ID: 18489889
[TBL] [Abstract][Full Text] [Related]
17. Chemo-prevention in superficial bladder cancer using mitomycin C: a survey of the practice patterns of British urologists.
Clarke NS; Basu S; Prescott S; Puri R
BJU Int; 2006 Apr; 97(4):716-9. PubMed ID: 16536760
[TBL] [Abstract][Full Text] [Related]
18. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome.
Herr HW
J Urol; 2000 Jan; 163(1):60-1; discussion 61-2. PubMed ID: 10604314
[TBL] [Abstract][Full Text] [Related]
19. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
Chou EC; Lin AT; Chen KK; Chang LS
Int J Urol; 2006 Jun; 13(6):682-5. PubMed ID: 16834642
[TBL] [Abstract][Full Text] [Related]
20. [Significance of random biopsies of healthy mucosa in superficial bladder tumor].
Fernández Gómez JM; Rodríguez Martínez JJ; Escaf Barmadah S; Pérez García J; García J; Casasola Chamorro J
Arch Esp Urol; 2000 Nov; 53(9):785-97. PubMed ID: 11196385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
